Core Viewpoint - MSCI announced the results of its quarterly index review, which includes the addition and removal of several stocks in the MSCI China Index and MSCI Global Standard Index, effective after market close on August 26 [1][7]. Group 1: New Additions to MSCI China Index - The MSCI China Index added 14 stocks, including Horizon Robotics-W, Lao Pu Gold, NetEase Cloud Music, Sangfor Technologies, and Citic Bank [1][3]. - Among the newly added stocks, Citic Bank is the largest by market capitalization in the MSCI Emerging Markets Index [1]. Group 2: Stocks Removed from MSCI China Index - A total of 17 stocks were removed from the MSCI China Index, including Yingjia Gongjiu, Oriental Yuhong, Supor, and Hisense Home Appliances [1][9][10]. Group 3: Implications of Index Changes - The inclusion of new stocks in the MSCI China Index is expected to attract significant passive investment flows on the effective date [7]. - The MSCI China A-Shares Onshore Index also saw adjustments, adding five stocks, including Citic Bank and Giant Network [10].

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the chemical preparation sector of A-shares is 1.0448 million yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 47% of the market, while those aged 60 and above account for only 4% [1] Group 2 - The top three highest-paid CFOs are Lü Hongbin from Dize Pharmaceutical with 4.2101 million yuan, Si Yanzha from Lizhu Group with 3.904 million yuan, and Lai Dequ from Kelun Pharmaceutical with 3 million yuan [2] - The largest salary decrease was observed for Xu Rongyi from Hainan Haiyao, with a year-on-year decline of 48.66% [2] - The highest salary increase was recorded for Wang Lin from Ailis, with a year-on-year increase of 104.6% [2]

责任编辑：公司观察 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有87家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到47%；60岁以上的CFO占比 为4%；50岁-60岁的CFO群体占比为39%；40岁及以下CFO群体占比为10%。其中，目前仍任职的最年 轻的上市公司CFO年龄33岁，为北陆药业的曾妮。 从CFO的学历分布看，拥有大专、本科、硕士、博士学历的CFO占比分别为9%、52%、38%、1%。其 中，获得博士学历的CFO仅一人，为恒瑞医药的刘健俊。 从薪酬分布看，A股化学制剂公司CFO年薪平均值为104.48万元。经统计，处于50万以下、50万-100 万、100万-20 ...

格隆汇8月8日｜MSCI公布指数成份股季度检讨结果，MSCI中国指数成份股，新增14只股份，剔出17只 股份。 新加入的股份包括老铺黄金(6181.HK)、药明合联(2268.HK)、美图(1357.HK)、网易云音乐(9899.HK)、 三生制药(1530.HK)、中信金融资产(2799.HK)、科伦博泰生物(6990.HK)、地平线机器人(9660.HK)等。 其余纳入指数A股包括指南针(300803.SZ)、中信银行A股(601998.SH)、巨人网络(002558.SZ)、艾力斯 (688578.SH)及景旺电子(603228.SH)。 剔出股份包括海信家电(0921.HK)、中升控股(0881.HK)、吉祥航空(603885.SH)、养元饮品(603156.SH) 等。 MSCI指，老铺黄金和中信银行是新兴市场指数的最大3只新增成分股的其中2只。 香港小型股指数加入耀才证券(1428.HK)和德林国际(1126.HK)2只股份，没有股份被剔除。 所有变动于8月26日收市后生效。 ...

| 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 2.80 | 225.46 | 80.52 | -15.41 | 平安证券股份有限公司 | 中信建投证券股份有限公司 | | | | | | 济南解放路证券营业部 | 济南经四路证券营业部 | （文章来源：证券时报网） 两融数据显示，该股最新融资余额为7.94亿元，近5日增加2208.32万元，增幅为2.86%。（数据宝） 8月7日艾力斯大宗交易一览 艾力斯8月7日大宗交易平台出现一笔成交，成交量2.80万股，成交金额225.46万元，大宗交易成交价为 80.52元，相对今日收盘价折价15.41%。该笔交易的买方营业部为平安证券股份有限公司济南解放路证 券营业部，卖方营业部为中信建投证券股份有限公司济南经四路证券营业部。 证券时报·数据宝统计显示，艾力斯今日收盘价为95.19元，下跌4.25%，日换手率为1.26%，成交额为 5.46亿元 ...

| 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | 交易日期 | 证券代码 | 证券简称 | 卖出营业部 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 平安证券股份有限 | 中信建投证券股份 | 艾力斯 | 2025-08-07 | 688578 | 80.52 | 225.46 | 2.8 | 公司济南解放路证 | 有限公司济南经四 | | Parks Arman Jald shops. III. Jury | Jack whole . I allery | | | | | | | | | 8月7日，艾力斯大宗交易成交2.8万股，成交额225.46万元，占当日总成交额的0.41%，成交价80.52元，较市场收盘价95.19元折价15.41%。 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 1.69% as of August 7, 2025, with mixed performance among constituent stocks [1] - Huada Zhizao led the gains with an increase of 4.42%, while Yuyuan Pharmaceutical and others experienced declines [1][5] - The market for the Sci-Tech Innovation Medical ETF managed by Harvest saw a turnover of 27.9% and a transaction volume of 65.88 million yuan, indicating active trading [3] Group 2 - As of August 6, 2025, the Sci-Tech Innovation Medical ETF reached a new high in scale at 237 million yuan, ranking first among comparable funds [3] - The ETF saw a net inflow of 2.96 million yuan recently, with a total of 17.65 million yuan accumulated over the last five trading days [3] - The ETF's net value increased by 49.39% over the past year, with the highest monthly return recorded at 23.29% since its inception [3] Group 3 - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading stocks including United Imaging Healthcare and BeiGene [3] - Minsheng Securities believes that domestic medical insurance policy support and overseas value recognition will sustain the ongoing trend of Chinese innovative drugs [5] - China has become a core procurement area for global trading, with traditional pharmaceutical companies accelerating their innovation and international expansion [5]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 新浪财经最新发布的《2024年度A股CFO数据报告》揭示了上市公司财务总监的薪酬格局。报告显示， 2024年A股上市公司CFO薪酬总额达42.70亿元，平均年薪为81.48万元。 其中，医药生物行业（申万一级）的CFO薪酬水平尤为突出，395家纳入统计的公司CFO平均年薪约为 91.97万元，显著高于全市场均值，超出幅度达12.8%。 | | | | 2024年医药生物行业的上海地区上市公司CFO薪酬前十 | | | | | --- | --- | --- | --- | --- | --- | --- | | 上市公司 | 行业(申万一级) | CFO | 年齡 | 学历 | 薪酬(万) | 24年总量收增长率(%) | | 上海医药 | 医药生物 | 沈波 | 53 | 硕士 | 305.4 | 5.75 | | 十米奥士 | 医药生物 | 陈乐奇 | 38 | 硕士 | 292.83 | 2.67 | | 迈威生物-U | 医药生物 | 华 ...

Group 1 - The core viewpoint highlights the strong performance and growth of the Kexin Pharmaceutical ETF managed by Jiashi, with significant trading activity and inflows [2] - As of August 4, the Kexin Pharmaceutical ETF Jiashi has seen a weekly average trading volume of 58.54 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 12.30 million yuan over the past two weeks, also leading among comparable funds [2] - The fund's net asset value has risen by 50.01% over the past year, placing it in the top 15.64% of index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - The biopharmaceutical industry is expected to stabilize and grow throughout 2025, supported by favorable policies for innovative drug development and medical equipment updates [5] - The transition to the 2.0 era of innovative drugs in China is marked by a qualitative improvement, with domestic new drugs expected to participate deeply in the global market over the next decade [4]

Core Insights - The article highlights the significant achievement of Ailis in the Chinese pharmaceutical industry, particularly with its drug Fumetinib, which has won the highest honor in intellectual property in China [1][2] - Ailis has successfully commercialized Fumetinib, establishing itself as a representative of innovation in the pharmaceutical sector, achieving a remarkable revenue growth and market capitalization increase [1][6] - Despite its success, Ailis faces challenges due to its heavy reliance on a single product, prompting the company to seek new growth opportunities [1][4][11] Group 1: Company Achievements - Ailis was founded in 2004 and has become a significant player in the pharmaceutical industry, particularly with the success of Fumetinib [3][4] - Fumetinib's sales revenue skyrocketed from 5.3 billion yuan in 2021 to 35.58 billion yuan in 2024, with a compound annual growth rate of 88.6% [4][6] - The company's stock price increased from 14.16 yuan to nearly 100 yuan, representing a growth of over 586%, leading to a market capitalization exceeding 40 billion yuan [6][7] Group 2: Market Dynamics - The EGFR inhibitor market in China reached a sales scale of 204.4 billion yuan in 2024, with a year-on-year growth of 19.5% [7][8] - Fumetinib's market share increased to 14.3% in 2024, while competitors like Osimertinib and Amivantamab faced challenges, allowing Ailis to capture market share [7][8] - The competitive landscape is intensifying with the entry of multiple new third-generation EGFR inhibitors and the development of fourth-generation drugs, posing a threat to Fumetinib's market position [8][9] Group 3: Strategic Responses - Ailis is focusing on deepening the development of Fumetinib through various clinical studies to expand its indications and market potential [11][12] - The company is pursuing a dual strategy of "independent research and development + collaborative partnerships" to build a diverse product portfolio [12][14] - Despite the ongoing growth, Ailis's revenue growth rate is showing signs of slowing down, indicating the need for new growth drivers beyond Fumetinib [12][14]